Premium
Recombinant granulocyte‐macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia
Author(s) -
Doney Kristine,
Storb Rainer,
Appelbaum Frederick R.,
Buckner C. Dean,
Sanders Jean,
Singer Jack,
Hansen John A.
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb08665.x
Subject(s) - medicine , chills , granulocyte macrophage colony stimulating factor , methylprednisolone , vomiting , immunology , nausea , gastroenterology , anti thymocyte globulin , immunosuppression , globulin , cytokine
Summary. Seventeen patients with aplastic anaemia were treated with recombinant human granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) for 14 d. Nonrespond‐ing patients were then treated with anti‐human thymocyte globulin (ATG), methylprednisolone and oxymetholone. Side‐effects of rhGM‐CSF included fever, nausea and vomiting, diarrhoea, bone pain, headache and chills. Two patients had sustained trilineage haemopoietic recovery after receiving only rhGM‐CSF. Of 11 patients who received immunosuppressive therapy, there was one complete response, two partial responses, one minimal response, and seven nonres‐ponses. Actuarial survival at 2 years is 64%. Early administration of rhGM‐CSF had no apparent effect on subsequent response to immunosuppressive therapy.